Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Verve Therapeutics to Participate in Upcoming Investor Conferences
-
Verve Therapeutics to Participate in Upcoming Investor Conferences
-
Presto to Become Publicly Traded Following Business Combination with Ventoux CCM Acquisition Corp. (VTAQ)
-
Presto, One of the Largest Labor Automation Technology Providers for the Hospitality Industry, to Become Publicly Traded Following Business Combination with Ventoux CCM Acquisition Corp.
-
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
-
4D Molecular Therapeutics to Participate in Upcoming Investor Conferences
-
Senti Bio to Participate in Chardan’s 6th Annual Genetic Medicines Conference
-
Senti Bio to Participate in Chardan’s 6th Annual Genetic Medicines Conference
-
Coave Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference
-
Form 425 Chardan NexTech Acquisit Filed by: Chardan NexTech Acquisition 2 Corp.
-
GenSight Biologics to Present at Upcoming Industry and Investor Conferences
-
Chardan NexTech Acquisition 2 Corp. Announces Effectiveness of Registration Statement and October 6, 2022 Special Meeting of Stockholders to Approve Business Combination with Dragonfly Energy Corp.
-
Form EFFECT Chardan NexTech Acquisit
-
Form 424B3 Chardan NexTech Acquisit
-
Ventoux CCM Acquisition (VTAQ) Stockholders Approve Proposed Business Combination with Presto
-
Ventoux CCM Acquisition Corp. Stockholders Approve Proposed Business Combination with Presto
-
Form S-4/A Chardan NexTech Acquisit
-
Form S-4/A Chardan NexTech Acquisit
-
UPDATE: Chardan Capital Markets Starts Outlook Therapeutics Incs. (OTLK) at Buy; Bullish on ONS-5010 for Wet AMD
-
Form 425 Chardan NexTech Acquisit Filed by: Chardan NexTech Acquisition 2 Corp.
-
CleanTech Acquisition Corp. (CLAQ) and Nauticus Robotics, Inc. Complete Business Combination (KITT)
-
CleanTech Acquisition Corp. and Nauticus Robotics, Inc. Complete Business Combination
-
CleanTech Acquisition Corp. and Nauticus Robotics, Inc. Complete Business Combination
-
Form 425 Chardan NexTech Acquisit Filed by: Chardan NexTech Acquisition 2 Corp.
-
MeiraGTx to Participate in Upcoming Investor Conferences
-
MeiraGTx to Participate in Upcoming Investor Conferences
-
Chardan Announces the Inaugural SPICI (Smart People in Cellular Immunotherapy) Symposium
-
UPDATE: Chardan Capital Markets Starts Purple Biotech Ltd. (PPBT) at Buy, PT $11, 'We forecast both CM24 and NT219 reaching the US market in 2027'
-
SQZ Biotechnologies to Present at Upcoming Investor Conferences
-
Genenta to Present at Upcoming Investor Conferences
-
Form 425 Chardan NexTech Acquisit Filed by: Chardan NexTech Acquisition 2 Corp.
-
Form 8-K Chardan NexTech Acquisit For: Sep 06
-
Form 425 Chardan NexTech Acquisit Filed by: Chardan NexTech Acquisition 2 Corp.
-
Chardan Announces Launch of ChEF (Chardan Equity Facility)
-
Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference
-
Form S-4/A Chardan NexTech Acquisit
-
Form SC 13G Chardan NexTech Acquisit Filed by: Vellar Opportunities Fund Master, Ltd.
-
Form 4 CHARDAN NEXTECH ACQUISIT For: Aug 18 Filed by: MIZUHO SECURITIES USA LLC
-
Form 3 CHARDAN NEXTECH ACQUISIT For: Aug 18 Filed by: MIZUHO SECURITIES USA LLC
-
Form 425 Chardan NexTech Acquisit Filed by: Chardan NexTech Acquisition 2 Corp.
-
Form 10-Q/A Chardan NexTech Acquisit For: Jun 30
-
Form 10-Q Chardan NexTech Acquisit For: Jun 30
-
VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options
-
CleanTech Acquisition Corp. Announces Effectiveness of Registration Statement and Date for Special Meeting to Approve Business Combination with Nauticus Robotics, Inc.
-
CleanTech Acquisition Corp. Announces Effectiveness of Registration Statement and Date for Special Meeting to Approve Business Combination with Nauticus Robotics, Inc.
-
AgeX Therapeutics Reports Second Quarter 2022 Financial Results
-
Form 425 Chardan NexTech Acquisit Filed by: Chardan NexTech Acquisition 2 Corp.
-
Form S-4/A Chardan NexTech Acquisit
-
Form 8-K Chardan NexTech Acquisit For: Aug 10
-
Form 425 Chardan NexTech Acquisit Filed by: Chardan NexTech Acquisition 2 Corp.

